Trimurthi Ltd

Novelix Pharmaceuticals Ltd has issued a corrigendum to its Extra-Ordinary General Meeting (EGM) notice dated June 4, 2026, for the EGM scheduled on July 1, 2026. The amendment pertains to Item No. 1 of the EGM notice and explanatory statement, specifically regarding a preferential allotment of 1,200,000 equity shares. Two proposed allottees, Sakshi Malani (150,000 shares) and Pallapothu Sivakrishna (25,000 shares), have been disqualified from receiving shares. This disqualification is due to violations of Regulation 159(1)(c) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as they sold shares within 90 trading days preceding the relevant date. The 175,000 disqualified shares will be re-allocated to three existing proposed allottees: Suman Rajiv Bihani, Vedant Rajiv Bihani, and Prakash Galda, with each receiving an additional 50,000 equity shares.

Novelix Pharmaceuticals Ltd. (formerly Trimurti Limited) has announced an Extra Ordinary General Meeting (EGM) scheduled for July 01, 2026, to be held via Video Conferencing. The primary agenda item is to consider and approve the issue of up to 12,00,000 equity shares on a preferential basis. These shares will be offered at an issue price of ₹57 each, comprising a face value of ₹10 and a premium of ₹47 per share. The meeting will also seek approval for related regulatory compliances under various sections of the Companies Act, 2013, and SEBI regulations.

Novelix Pharmaceuticals Ltd announced its Board of Directors has approved a preferential issue of 12,00,000 equity shares at ₹57 each to non-promoters, aiming to raise ₹6.84 crore. This move is subject to shareholder and regulatory approvals. The funds will be utilized for additional capital raising. The issuance price includes a face value of ₹10 and a premium of ₹47 per share.

Novelix Pharmaceuticals Ltd has announced the details for its upcoming Extraordinary General Meeting (EGM). The EGM will be held on Wednesday, July 1, 2026, at 3:30 PM via video conferencing. The company has set Wednesday, June 24, 2026, as the cut-off date for determining eligibility for remote e-voting. The remote e-voting period will commence on Sunday, June 28, 2026, at 9:00 AM and conclude on Tuesday, June 30, 2026, at 5:00 PM. Shareholders can cast their votes electronically during this period.

Novelix Pharmaceuticals Ltd. has entered into a production scale-up agreement with GMBU e.V., Germany, for Astaxanthin. This follows successful pilot-scale production. The agreement aims to commercialize Astaxanthin production at Novelix's Hyderabad facilities. The company confirmed that GMBU e.V. is not a related party, and the transaction is at arm's length. This marks a significant step in commercializing the product.

Novelix Pharmaceuticals Ltd has received disclosures under SEBI's takeover regulations regarding the allotment of equity shares. Gattu Gnana Prakash and Arati Gattu were allotted 50,000 and 100,000 equity shares, respectively, on May 29, 2026, following the conversion of warrants issued via preferential allotment. This transaction increases Gattu Gnana Prakash's direct shareholding and voting rights in the company. The total equity share capital of the company has increased post-acquisition.

Novelix Pharmaceuticals Ltd has disclosed a significant share acquisition by Vupparapalli Chandrasekhar Reddy and Vupparapalli Pavani. Vupparapalli Chandrasekhar Reddy was allotted 5,60,000 equity shares on May 29, 2026, pursuant to the conversion of warrants issued via preferential allotment. This transaction increases their combined shareholding to 11.95% of the company's total equity. The acquisition was completed through the conversion of warrants on a preferential allotment basis, impacting the company's equity structure and promoter holdings.

Novelix Pharmaceuticals Ltd has announced that Srinidhi Fine-Chemicals LLP and Narahari Belide have been allotted 9.5 lakh equity shares and 1.5 lakh equity shares respectively, totaling 11 lakh shares, pursuant to the conversion of warrants issued via preferential allotment. This transaction, which occurred on May 29, 2026, results in Srinidhi Fine-Chemicals LLP holding 79.02 lakh shares and Narahari Belide holding 8.00 lakh shares post-acquisition. The total diluted share capital of the company after this acquisition stands at approximately 23.895 million equity shares.

Novelix Pharmaceuticals Ltd has announced the allotment of 9,50,000 equity shares to its promoters following the conversion of warrants. Srinidhi Fine-Chemicals LLP was allotted 8,00,000 shares, while Narahari Belide received 1,50,000 shares. This preferential allotment, executed on May 29, 2026, increases the company's total equity share capital to 23,895,000 shares.

Novelix Pharmaceuticals Ltd has scheduled a Board of Directors meeting on June 4, 2026, to consider and approve the issuance of securities on a preferential basis, adopt the Draft Notice of Extra Ordinary General Meeting, fix the EGM date, time, and venue, and appoint a scrutinizer for the E-voting process. The trading window will be closed from June 1, 2026, until 48 hours after the announcement is made public.